Tricyclic Compounds for SYNGAP1 Gene Expression Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for neurodevelopmental disorders such as SYNGAP1-Related Disorder and synaptopathies like DLG4-related synaptopathy lack a cure or specific treatment for the underlying condition, and many symptoms are drug-resistant, leading to challenges in improving communication, behavior, sleep, sensory processing, and seizure control.
Innovation Solution
Administering a therapeutically effective amount of a tricyclic organic compound, such as nortriptyline or amitriptyline, to modulate SYNGAP1 gene expression, thereby increasing synaptic plasticity and decreasing neuronal excitability, which can improve symptoms by increasing functional SynGAP protein and correcting synaptic deficiencies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies (physical therapy, occupational therapy, speech therapy, antiepileptic medications) are administered to SYNGAP1 patients, then some skills and milestones can be improved to a certain extent, but there is no cure or specific treatment for the underlying condition and many symptoms become treatment-resistant
Solution Approach 1:
The patent uses tricyclic organic compounds as intermediary substances that modulate SYNGAP1 gene expression indirectly. These compounds act as mediators between the external treatment and the genetic defect, correcting the underlying molecular dysfunction rather than merely managing symptoms. This approach addresses treatment resistance by targeting the root cause through a chemical intermediary that regulates gene expression.
Solution Approach 2:
The invention changes the parameter of gene expression levels by administering tricyclic organic compounds that modulate SYNGAP1 transcription. This parameter change approach transforms the therapeutic strategy from symptom management to correcting the fundamental molecular parameter (gene expression) that is defective in SYNGAP1-related disorders, thereby overcoming treatment resistance.
2Productivity
If intense therapy is provided to SYNGAP1 patients, then skills and milestones can be improved to a certain extent, but the underlying condition remains uncured and symptoms become drug-resistant
Solution Approach 1:
The patent applies preliminary action by correcting the SYNGAP1 gene expression defect before it leads to irreversible neurological damage and treatment resistance. By intervening at the molecular level to restore proper gene expression, the treatment addresses the root cause proactively, preventing the development of drug-resistant symptoms and ensuring long-term therapeutic sustainability rather than merely responding to established deficits.
3Ease of operation
If traditional symptom management therapies are used, then some behavioral and communication improvements can be achieved, but the underlying genetic defect remains untreated
Solution Approach 1:
The patent replaces the mechanical/system-level intervention of traditional therapies (physical therapy, occupational therapy, behavioral interventions) with a molecular-level chemical intervention. Instead of using complex multi-session therapeutic programs, the invention uses tricyclic organic compounds that directly modulate gene expression at the molecular level, substituting a simple chemical mechanism for complex mechanical therapy systems while achieving curative effects.
Data Source
AI summary
Methods of treatment of neurodevelopmental disorders via administration of organic tricyclic compounds are described. Organic tricyclic compounds administered in the method of the invention include nortriptyline, amitriptyline and their pharmaceutically acceptable salts. Pharmaceutical compositions and dosage forms containing organic tricyclic compounds are also described.